List view / Grid view

Parkinson's disease

Antidepressant could slow Parkinson’s disease

6 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Nortriptyline, which has been used to treat depression has been found to stop the growth of abnormal proteins on the brain...

news

Asthma medicine halves risk of Parkinson’s

4 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Researchers have found that asthma medicine can halve a patient's risk of developing Parkinson's disease...

news

Metformin may help in Parkinson’s disease

30 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Researchers have found that a diabetes drug may help in certain types of Parkinson’s disease...

news

New drug may slow progression of Parkinson’s disease

1 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

A preclinical model of Parkinson's disease was employed to compare the effects of the dopamine agonist ropinirole to a new drug...

news

NICE publishes new Parkinson’s clinical guidance

21 July 2017 | By Niamh Marriott (European Pharmaceutical Review)

Parkinson’s disease is one of the most common neurological conditions, affecting an estimated 130,000 people in the UK, with an annual incidence of around 15-20 per 100,000. It mainly affects people aged 50 or over.

news

Motor neurone disease onset delayed by AI-discovered drug

25 May 2017 | By Niamh Marriott, Junior Editor

The study assessed the efficacy of a drug candidate proposed by BenevolentAI’s artificial Intelligence technology for Motor Neuron Disease (MND)...

news

Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology

18 April 2017 | By Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).

news

Success for Renown’s Phase I study to treat “OFF” episodes in Parkinson’s patients

22 March 2017 | By Niamh Marriott, Junior Editor

The study intended to compare the plasma concentrations of sub-lingual apomorphine spray against the currently approved formulation...

news

Prothena’s Phase 1b Parkinson’s disease study showed robust antibody CNS penetration

11 November 2016 | By Niamh Louise Marriott, Digital Content Producer

Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease...

news

Prexton successfully completes phase 1 Parkinson’s disease trial

20 September 2016 | By Niamh Louise Marriott, Digital Content Producer

This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally...

news

Biomarker breakthrough could improve Parkinson’s treatment

16 August 2016 | By University of Florida

Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new experimental treatments to slow or stop the disease’s progression...

news

Collaboration to explore nilotinib as a potential treatment for Parkinson’s

13 July 2016 | By Victoria White, Digital Content Producer

Preclinical studies have shown that cancer drug nilotinib may protect neuronal cells from Parkinson's pathology by inhibiting the activity of c-Abl...

news